TechConnect Innovation Program

New therapeutics for E6AP-associated disorders

LSU Health Sciences Center - New Orleans, Louisiana, United States

TECHNOLOGY SUMMARY

A team of investigators have discovered a novel small-molecule for the treatment of HPV-associated cervical cancer, hepatitis C pathology, and certain instances of Autism Spectrum Disorder. The molecular target, binding site, and mechanism of action of this therapeutic have been characterized. Proof-of-principle studies showing efficacy and specificity have been completed.

Primary Application Area: Pharmaceuticals & Personal Care

Technology Development Status: Prototype

Technology Readiness Level: TRL 3

FIGURES OF MERIT

Value Proposition: This technology leverages the identification of a previously unknown mechanism required for E6AP activity into the development of a therapeutic for E6AP-associated disorders. Proof-of-principle studies have already been performed, presenting a pharmaceutical company a unique opportunity to optimize a lead compound into a marketable therapeutic.

SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

Showcase Booth #: 737

Website: www.lsuhsc.edu

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date: NIH GM034009

Primary Sources of Funding: Federal Grant, University

Looking for: Both Funding and Development Partners